Now available BKEMV™

BKEMV™ (eculizumab-aeeb) injection, for intravenous use, is a complement inhibitor indicated for:

• The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

• The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

View full prescribing information.